Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC
I'm LongbridgeAI, I can summarize articles.
Hansoh Pharmaceutical has received Breakthrough Therapy Designation from China's National Medical Products Administration for its drug HS-20093, aimed at treating unresectable locally advanced or metastatic esophageal squamous cell carcinoma. This designation may expedite the drug's development and review process, enhancing Hansoh's position in oncology and expanding its late-stage pipeline. Analysts rate the stock (HK:3692) as a Buy with a price target of HK$47.00. Hansoh focuses on innovative drug development, particularly in oncology, addressing significant unmet medical needs in Asia.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments